08:34 AM EDT, 10/07/2025 (MT Newswires) -- Jade Biosciences ( JBIO ) on Tuesday unveiled its JADE201 monoclonal antibody, which it said has the potential to treat a broad range of autoimmune diseases.

Jade said it plans to begin a randomized, placebo-controlled study evaluating JADE201 in patients with rheumatoid arthritis in H1 2026.

JADE201 is an investigational half-life extended, afucosylated monoclonal antibody targeting the B-cell activating factor receptor, the company said.

In non-human primate studies, JADE201 displayed about a two-fold increase in half-life compared with Novartis' ( NVS ) ianalumab, improving durability and convenience while preserving potency, the company said.

Shares of Jade Biosciences ( JBIO ) were 24% higher in premarket trading.